Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novartis Ag ADR
(NY:
NVS
)
105.40
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Jun 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novartis Ag ADR
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
27
28
Next >
Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering
January 24, 2023
Via
Benzinga
3 Drug Stocks With Promising Pipelines for 2023
January 23, 2023
These 3 drug stocks with promising pipelines are in position to reward investors in 2023 due to multiple factors.
Via
InvestorPlace
Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects
January 19, 2023
Psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) has successfully completed two drug discovery projects with leading scientists at the Hebrew University of Jerusalem.
Via
Benzinga
Analyst Views Novo Nordisk's Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly's Tirzepatide
January 19, 2023
Cantor Fitzgerald published around 40-page deep dive ahead of Novo Nordisk A/S's (NYSE: NVO) SELECT CV outcomes study, which is guided to complete in ~mid-2023.
Via
Benzinga
Novartis CEO Refutes Recent Report Of Weighing Options For Ophthalmology, Respiratory Units
January 10, 2023
Novartis AG (NYSE: NVS) said it would narrow its focus on five core therapeutic areas, including cardiovascular, immunology, neurodegenerative diseases, solid tumors, and hematology.
Via
Benzinga
Hopeful Golden Cross Forms On Novartis's Chart
December 26, 2022
Via
Benzinga
5 Value Stocks In The Healthcare Sector
December 26, 2022
Via
Benzinga
A Bullish Sign Appears On Novartis's Chart
December 23, 2022
Via
Benzinga
Novartis' Rare Blood Disorder Therapy Aces Second Late-Stage Trial
December 08, 2022
Via
Benzinga
3 Biotech Companies to Watch in 2023
January 06, 2023
These biotech companies to watch are remarkably strong businesses that offer healthy upside potential as we head into a new year.
Via
InvestorPlace
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
January 06, 2023
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.
Via
Investor's Business Daily
2 Top Biotech Stocks to Buy Right Now
January 06, 2023
These two pharmaceutical companies pay market-beating dividends to shareholders.
Via
The Motley Fool
GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca
December 30, 2022
GSK plc (NYSE: GSK) chief commercial officer Luke Miels says the company is looking at M&A targets that are under-appreciated worth $1 billion-$2.5 billion and avoid getting into a 'bidding war.'
Via
Benzinga
2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond
December 29, 2022
These two biotechs are flying high right now.
Via
The Motley Fool
Elon Musk Tells Employees Tesla Will Be 'Most Valuable Company On Earth, Sam Bankman-Fried Set To Enter Plea On Fraud Case, Twitter 'Should Feel Faster': Today's Top Stories
December 29, 2022
Reuters
Via
Benzinga
Novartis Settles Antitrust Cases Related To Generic Entry For Hypertension Drug
December 29, 2022
Novartis AG (NYSE: NVS) will pay $245 million to end antitrust litigation accusing the company of trying to delay the U.S. launch of generic versions of its Exforge, which treats hypertension to lower...
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
December 23, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
3 Ridiculously Cheap Dividend Stocks That Yield More Than 3%
December 22, 2022
You're getting a lot of bang for your buck with these stocks.
Via
The Motley Fool
Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says
December 20, 2022
Via
Benzinga
Pfizer, Novartis Are Among Overbought Healthcare Stocks: Are They Worth A Look?
December 14, 2022
The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies. Here’s the latest list of major overbought players in this sector, with an RSI...
Via
Benzinga
A Career Politician Who Regularly Trades The SPY, Picked Up There 3 High Yielding ETFs Instead
December 13, 2022
Representative Robert Wittman (R-VA) is the vice-ranking member of the House Armed Services Committee and also serves on the Committee on Natural Resources.
Via
Benzinga
Novartis Shares Detailed Results From Experimental Drug For Rare Blood Disorder
December 13, 2022
Via
Benzinga
Why Merck's $250 Million Investment In Moderna May Have Just Paid Off
December 13, 2022
Merck opted into Moderna's cancer vaccine. Now, the companies have Phase 2 data.
Via
Investor's Business Daily
CLVS Stock Alert: What to Know as Clovis Oncology Files for Bankruptcy
December 12, 2022
Clovis Oncology (CLVS) stock is on the move Monday as investors react to the pharmaceutical company filing for bankruptcy protection.
Via
InvestorPlace
Erasca Oulicenses Its Mid-Stage Cancer Program To Novartis, Raises $100M Via Equity Offering
December 09, 2022
Via
Benzinga
3 Hot Stocks That Could Live Up to Their Lofty Valuations
December 08, 2022
These companies have long runways of growth ahead
Via
The Motley Fool
MorphoSys Inks Licensing Agreement With Novartis For Preclinical Cancer Programs
December 07, 2022
Via
Benzinga
Novartis' Kisqali Prolongs Progression Free Survival Benefit In Metastatic Breast Cancer Versus Chemo
December 07, 2022
Via
Benzinga
First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM
December 02, 2022
By Rachael Green, Benzinga
Via
News Direct
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
December 02, 2022
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.
Via
Benzinga
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
27
28
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.